Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Author(s):

Jesper D. Gunst, Jesper F. Højen, Marie H. Pahus, Miriam Rosás-Umbert, Birgitte Stiksrud, James H. McMahon, Paul W. Denton, Henrik Nielsen, Isik S. Johansen, Thomas Benfield, Steffen Leth, Jan Gerstoft, Lars Østergaard, Mariane H. Schleimann, Rikke Olesen, Henrik Støvring, Line Vibholm, Nina Weis, Anne M. Dyrhol-Riise, Karen B.H. Pedersen, Jillian S.Y. Lau, Dennis C. Copertino, Noemi Linden, Tan T. Huynh, Victor Ramos, R. Brad Jones, Sharon R. Lewin, Martin Tolstrup, Thomas A. Rasmussen, Michel C. Nussenzweig, Marina Caskey, Dag Henrik Reikvam, Ole S. Søgaard

Details:

Nature Medicine, Volume 29, Issue 10, 2023-10-01

Article Link: Click here

Affiliations:

• Rockefeller University
• The Peter Doherty Institute for Infection and Immunity
• Oslo Universitetssykehus
• Københavns Universitet
• Aarhus Universitet
• Aarhus Universitetshospital
• Aalborg University
• Syddansk Universitet
• University of Nebraska Omaha
• Odense Universitetshospital
• Aalborg Universitetshospital
• Copenhagen University Hospital
• Universitetet i Oslo
• The Alfred
• Weill Cornell Medicine
• Rigshospitalet
• Royal Melbourne Hospital
• Weill Cornell Graduate School of Medical Sciences
• Gødstrup Hospital